Results 111 to 120 of about 5,232 (145)

Giant Cervicothoracic Madelung Disease Presenting with Airway Compromise: A Case Report from Ethiopia. [PDF]

Surg Case Rep
Oljira AM, Negasa OB, Wakesa DG, Keneni SA, Bikila BN, Dammesa CA, Bayisa TH, Gonfa RW, Hamido OA, Geleta DG.   +9 more
europepmc   +1 more source

Patient in Mayfield Head Pins Requiring Prone Bronchoscopy for Mucus Plug Obstruction: A Case Report. [PDF]

Cureus
Veligandla S, Pasca IF, Radhakrishnan T, Arif H, Ignacio GCT, Sinha A.   +5 more
europepmc   +1 more source

Airway Management for Tracheoesophageal Fistula Repair and Tracheal Repair Under Veno-Venous Extracorporeal Membrane Oxygenation. [PDF]

Cureus
Koh IE, Thangavelautham S, Kothandan H.
europepmc   +1 more source

Inhaler-Related Greenhouse Gas Emissions in the US: A Serial Cross-Sectional Analysis.

JAMA
Feldman WB, Han J, Raymakers AJN, Furie GL, Chesebro BB.   +4 more
europepmc   +1 more source

An overview of glycopyrrolate/eFlow® CS in COPD

Expert Review of Respiratory Medicine, 2018
Introduction: COPD is highly prevalent in the US and globally, requiring new treatment strategies due to the high disease burden and increase in the aging population.
Edward M Kerwin, Gary T Ferguson
exaly   +2 more sources

Nebulized Glycopyrrolate for Drooling in a Motor Neuron Patient [PDF]

Journal of Pain and Symptom Management, 2002
Rebecca Strutt, null Fachpm, Belinda Fardell, Richard Chye, null Ffpmanzca, null Fachpm   +5 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The Effect of Nebulized Glycopyrrolate on Posterior Drooling in Patients with Brain Injury

American Journal of Physical Medicine and Rehabilitation, 2017
Posterior drooling, which can lead to substantial respiratory morbidity, including unexplained lung diseases and recurrent pneumonia, is an important issue in the rehabilitation unit. There are various treatment options for posterior drooling, including pharmacologic therapy, oral motor or behavioral therapy, biofeedback, local glandular injection of ...
Seung Beom Woo, Zee-Ihn Lee, Jong Min Kim   +2 more
exaly   +3 more sources

An Ultrasensitive LC–MS/MS Method and Application to Clinical Dose-Range Finding for Glycopyrrolate via an e-Nebulizer

Bioanalysis, 2021
Aim: Glycopyrrolate (GLY) has been widely used to treat chronic obstructive pulmonary disease (COPD). Recent technical advancement significantly improves the drug delivery efficiency. In a clinical dose-range determination study via electronic nebulizer, the starting dose was as low as 3-μg, thus, a bioanalytical method capable of measuring down to sub-
Yu-Luan Chen, Weimin Wang, Lei Shi, John Eddy   +3 more
openaire   +2 more sources

Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study [PDF]

Respiratory Medicine, 2017
The use of long-acting bronchodilators is an essential component of the management of chronic obstructive pulmonary disease (COPD). The GOLDEN 5 Phase III, randomized, active-controlled, open-label study was conducted to evaluate the long-term safety and tolerability of a nebulized glycopyrrolate formulation (SUN-101) delivered via the investigational ...
Robert Tosiello, Edward M Kerwin, Gary T Ferguson   +2 more
exaly   +3 more sources

Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD

European Respiratory Journal, 2011
Introduction: EP-101 is a long-acting muscarinic antagonist formulation of glycopyrrolate optimized for nebulization in development for the treatment of COPD. This dose-ranging study assessed the efficacy and safety of single doses of nebulized EP-101 in patients with COPD.
Dave Singh, Brian Leaker, Ahmet Tutuncu
openaire   +1 more source